Business Wire

NeoTract Welcomes UK Government Announcement to Remove Barriers to Adoption of the UroLift® System for BPH Care for Every NHS Hospital in England

Del

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today welcomed the announcement that the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH) has been acknowledged by the UK Government as one of only seven Accelerated Access Collaborative “Rapid Uptake Products.”

The UroLift System will now benefit from support from the Accelerated Access Collaborative to rapidly increase its uptake in the NHS. This enables transformative products to reach patients as quickly as possible through streamlined regulatory and market access decisions.

Neil Barber, Consultant Urologist, Frimley Health NHS Foundation Trust, was the first surgeon to routinely offer the UroLift System on the NHS. Mr. Barber said, “I am very pleased by this news. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear. What was evident from the beginning was that this is an effective day case procedure that, for the first time, preserves sexual function; we could offer most patients the likely prospect going home catheter-free; and they would experience a rapid improvement in symptoms and a return to normal activity with days rather than weeks as is the case for more standard surgical options.

“What we have learned in the NHS setting since the first procedures in 2014 is that the UroLift System has hugely helped us to improve the use of our resources. In my own Trust, we have been able to relocate the site of operation from the classical operating theatre to a procedure or minor ops room, and we are able to perform up to six UroLift System procedures on one list. This helps us to release precious capacity and reduce waiting times in other parts of our service.”

Teleflex Interventional Urology EMEA Vice President and General Manager, Justin Hall, said: “We are humbled and honored to hear that the UroLift System is one of the seven products that Accelerated Access Collaborative has chosen to support, enabling rapid increase in their uptake.

The inclusion of the UroLift System into the Accelerated Access Collaborative Rapid Uptake Products list follows the decision by NHS England in 2017 to name the treatment as one of the first recipients of the first Innovation and Technology Tariff, which essentially helped to fast track this minimally invasive, day case treatment into the NHS.

Mr. Hall added, “Today’s announcement shows that the Government acknowledges the treatment’s unique clinical benefits and our quality of robust clinical evidence, and increasingly, real world data, gathered from NHS urologists. Their experience shows that using the UroLift System allows them to deliver benefits for NHS urology departments: in terms of reducing overall costs and complications; saving substantial numbers of bed days; and hours of operating theatre time. The UroLift System potentially frees capacity for urologists to focus on critical cancer targets and waiting times, reducing delays in urgent and planned surgery.

“Our close partnership with NHS clinicians and regulators is enabling a true service transformation: not only for men and their treatment options but also in terms of developing a methodology of how to adopt a disruptive healthcare technology, such as The UroLift System, and embed it into the NHS, in a comparatively markedly shorter time than previous innovations.”

Jean-Luc Dianda, President, EMEA,Teleflex, said, “The UroLift System is a recent acquisition for Teleflex, and we believe it perfectly fits our mission statement to deliver medical technologies designed to improve the health and quality of people’s lives. Today’s announcement demonstrates that the treatment is now also additionally acknowledged as a transformative technology within a major public healthcare system.”

About the UroLift ® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Nearly 70,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® System and Weck® – trusted brands united by a common sense of purpose.

Neil Barber is a paid consultant to NeoTract | Teleflex Interventional Urology.

MAC00884-01 Rev A

Contact information

For Teleflex Incorporated:
Jake Elguicze, 001 610.948.2836
Treasurer and Vice President, Investor Relations
or
Media:
Gloucester Road Communications
Amanda Hayhurst, 0044 772 0205581

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SES: First Quarter 2019 Results26.4.2019 06:00:00 CESTPressemelding

SES S.A. announced its financial results for the three months ended 31 March 2019 with revenue and EBITDA in line with company expectations and SES on track to deliver on its 2019 financial outlook. Continued focus on execution has delivered major wins in the Networks business which is soon to be enhanced with the addition of four new O3b satellites, successfully launched at the beginning of April 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005955/en/ First Quarter 2019 Results Key financial highlights Reported revenue of EUR 480.6 million, (down 2.3% at constant FX(1)) in line with SES’ expectations Underlying revenue(2) of EUR 473.9 million; down 3.1%(1) (Video: -7.3%(1,2) and Networks +5.4%(1,2)) EBITDA of EUR 290.1 million representing a margin of 60.4% (Q1 2018: 63.7%); 62.1% excluding restructuring charge Net profit attributable to SES shareholders of EUR 72.2 million Free Cash Flow before financing acti

Wenco and Hitachi Construction Machinery Announce Open and Interoperable Partner Ecosystem for Autonomous Mining25.4.2019 23:30:00 CESTPressemelding

Hitachi Construction Machinery Co., Ltd. (TOKYO: 6305) (“HCM”) is pleased to announce its vision for autonomous mining — an open, interoperable ecosystem of partners that integrate their systems alongside existing mine infrastructure. Grounded in support for ISO Standards and a drive to encourage new entrants into the mining industry, HCM is pioneering this open and interoperable approach to autonomy among global mining technology leaders. With this announcement, HCM is publicly declaring support for standards-based autonomy and is offering its interoperable technology to assist mining customers in integrating new vendors into their existing infrastructure. HCM’s support for open, interoperable autonomy is based on its philosophy for its partner-focused Solution Linkage platform. “Open innovation is the guiding technological philosophy for Solution Linkage,” says Vice President and Executive Officer, Chief Technology Officer Hideshi Fukumoto. “Based on this philosophy, HCM is announcin

Garth Brooks Makes Mobile Game Debut in Words With Friends, Announces Final Pre-Order Window for The Legacy Collection25.4.2019 19:30:00 CESTPressemelding

Today, Zynga Inc. (Nasdaq: ZNGA), global leader in interactive entertainment, announced a collaboration with Garth Brooks, in its hit game, Words With Friends 2 . Kicking off a multi-month celebration of the game franchise’s 10th anniversary, and Brooks’ unprecedented career as a recording artist, players and fans will be treated to Garth-themed in-game activities and ongoing announcements starting with today’s reveal of ‘Journey’ as the game’s ‘Word of the Year’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005903/en/ Garth Brooks LEGACY COLLECTION (Graphic: Business Wire) Garth Brooks and Words With Friends are celebrating their 2019 milestones by giving fans new ways to interact with Garth and the game. On May 1st, Brooks will co-host Words With Friends LIVE, the nightly trivia game broadcast within Words With Friends 2. In conjunction, the FINAL pre-order window for special numbered editions of The Legacy Collect

Nordson EFD Introduces the Contact versus Jet Dispensing White Paper25.4.2019 12:16:00 CESTPressemelding

Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is pleased to introduce its Contact vs. Jet Dispensing white paper. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005027/en/ As products continue to get smaller and smaller, Nordson EFD has developed new solutions to address this growing need to apply precise, repeatable micro-deposits of assembly fluids in production processes worldwide. “We understand the challenges manufacturers face when their process requires bonding tiny substrates and components together,” said Peter Langer, Business Unit Director of Valves at Nordson EFD. “The deposit tolerance requirements are considerable. And there are a number of variables to consider in order to choose the right dispensing method.” This white paper helps manufacturers understand the difference between two of the most common dispensing methods. Contact dispe

Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe25.4.2019 12:15:00 CESTPressemelding

Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005180/en/ Trident® HD Specimen Radiography System (Photo: Business Wire) The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. The new Trident HD system, which recently received FDA clearance in the US and a CE Mark in Europe, also features a bigger detector that allows for complete imaging of larger breast surgical specimens, along with a wide range of surgical and biopsy sa

Velodyne Lidar, Nikon Announce Manufacturing Agreement for Mass Production of Velodyne Lidar Sensors25.4.2019 12:00:00 CESTPressemelding

Velodyne Lidar, Inc. today announced an agreement with Nikon Corporation, under which Sendai Nikon Corporation, a Nikon subsidiary, will manufacture lidar sensors for Velodyne with plans to start mass production in the second half of 2019. The partnership cements Velodyne’s manufacturing plan and expands its lead in the global lidar sensor market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005236/en/ Velodyne provides the smartest, most powerful lidar solutions for vehicle autonomy and driver assistance. (Photo: Business Wire) “Mass production of our high-performance lidar sensors is key to advancing Velodyne’s immediate plans to expand sales in North America, Europe, and Asia,” said Marta Hall, President and CBDO, Velodyne Lidar. “With this partnership, Velodyne affirms its leadership role in designing, producing, and selling lidar for worldwide implementation. For years, Velodyne has been perfecting lidar technol